A. Rawahi, T. Lopes, A. Bristow, R. Bryant, A. Elattar et al., Surgical cytoreduction for recurrent epithelial ovarian cancer, Cochrane Database Syst Rev, vol.2, p.8765, 2013.

S. Eisenkop, N. Spirtos, and W. Lin, ???Optimal??? cytoreduction for advanced epithelial ovarian cancer: A commentary, Gynecologic Oncology, vol.103, issue.1, pp.329-364, 2006.
DOI : 10.1016/j.ygyno.2006.07.004

I. Vergote, F. Amant, G. Kristensen, T. Ehlen, N. Reed et al., Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer, European Journal of Cancer, vol.47, issue.3, pp.88-92, 2011.
DOI : 10.1016/S0959-8049(11)70152-6

D. Elias, D. Goéré, F. Dumont, C. Honoré, P. Dartigues et al., Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases, European Journal of Cancer, vol.50, issue.2, 2013.
DOI : 10.1016/j.ejca.2013.09.024

P. Agostinis, K. Berg, K. Cengel, T. Foster, A. Girotti et al., Photodynamic therapy of cancer: An update, CA: A Cancer Journal for Clinicians, vol.4, issue.1, pp.250-81, 2011.
DOI : 10.3322/caac.20114

M. Ascencio, M. Delemer, M. Farine, E. Jouve, P. Collinet et al., Evaluation of ALA- PDT of ovarian cancer in the Fisher 344 rat tumor model. Photodiagnosis PhotodynTher, pp.254-60, 2007.

R. Schneider, F. Schmitt, C. Frochot, Y. Fort, N. Lourette et al., Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy, Bioorganic & Medicinal Chemistry, vol.13, issue.8, 2005.
DOI : 10.1016/j.bmc.2005.02.025

URL : https://hal.archives-ouvertes.fr/hal-00200165

J. Gravier, R. Schneider, C. Frochot, T. Bastogne, F. Schmitt et al., -tetra(Hydroxyphenyl)chlorin-Like Photosensitizer Selectivity with Folate-Based Targeted Delivery. Synthesis and in Vivo Delivery Studies, Journal of Medicinal Chemistry, vol.51, issue.13, pp.3867-77, 2008.
DOI : 10.1021/jm800125a

URL : https://hal.archives-ouvertes.fr/hal-00758622

F. Moret, D. Scheglmann, and E. Reddi, Folate-targeted PEGylated liposomes improve the selectivity of PDT with meta-tetra(hydroxyphenyl)chlorin (m-THPC), Photochemical & Photobiological Sciences, vol.7, issue.5, p.823, 2013.
DOI : 10.1039/c3pp25384h

D. Li, P. Li, H. Lin, Z. Jiang, L. Guo et al., A novel chlorin???PEG???folate conjugate with higher water solubility, lower cytotoxicity, better tumor targeting and photodynamic activity, Journal of Photochemistry and Photobiology B: Biology, vol.127, pp.28-37, 2009.
DOI : 10.1016/j.jphotobiol.2013.06.008

S. Choi and J. Mason, Folate and Carcinogenesis: An Integrated Scheme, J Nutr, 2000.

E. Despierre, S. Lambrechts, K. Leunen, P. Berteloot, P. Neven et al., Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy, Gynecologic Oncology, vol.130, issue.1, pp.192-201, 2013.
DOI : 10.1016/j.ygyno.2013.03.024

A. Antony and . Folate-receptors, Folate Receptors, Annual Review of Nutrition, vol.16, issue.1, pp.501-522, 1996.
DOI : 10.1146/annurev.nu.16.070196.002441

C. Leamon and P. Low, Folate-mediated targeting: from diagnostics to drug and gene delivery, Drug Discovery Today, vol.6, issue.1, pp.44-51, 2001.
DOI : 10.1016/S1359-6446(00)01594-4

J. Sudimack and R. Lee, Targeted drug delivery via the folate receptor, Advanced Drug Delivery Reviews, vol.41, issue.2, pp.147-62, 2000.
DOI : 10.1016/S0169-409X(99)00062-9

N. Parker, M. Turk, E. Westrick, J. Lewis, P. Low et al., Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Analytical Biochemistry, vol.338, issue.2, pp.284-93, 2005.
DOI : 10.1016/j.ab.2004.12.026

K. Kalli, A. Oberg, G. Keeney, T. Christianson, P. Low et al., Folate receptor alpha as a tumor target in epithelial ovarian cancer, Gynecologic Oncology, vol.108, issue.3, 2008.
DOI : 10.1016/j.ygyno.2007.11.020

S. Markert, S. Lassmann, B. Gabriel, M. Klar, M. Werner et al., Alpha-folate Receptor Expression in Epithelial Ovarian Carcinoma and Non-neoplastic Ovarian Tissue, Anticancer Res, vol.28, issue.6A, pp.3567-72, 2008.

H. Elnakat and M. Ratnam, Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Advanced Drug Delivery Reviews, vol.56, issue.8, pp.1067-84, 2004.
DOI : 10.1016/j.addr.2004.01.001

O. Shannessy, D. Somers, E. Smale, R. Fu, and Y. , Expression of folate receptor-? (FRA)

L. Crane, H. Arts, M. Oosten, P. Low, A. Zee et al., The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer, CellOncol, 2011.

Y. Chen, M. Chang, C. Huang, Y. Chiang, H. Lin et al., Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response, Molecular Oncology, vol.280, issue.2, pp.360-369, 2012.
DOI : 10.1016/j.molonc.2011.11.010

G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli et al., Overexpression of folate binding protein in ovarian cancers, International Journal of Cancer, vol.75, issue.2, pp.193-201, 1997.
DOI : 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F

M. Siu, D. Kong, H. Chan, E. Wong, P. Ip et al., Paradoxical Impact of Two Folate Receptors, FR?? and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome, PLoS ONE, vol.68, issue.11, p.47201, 2012.
DOI : 10.1371/journal.pone.0047201.t003

F. Bottero, A. Tomassetti, S. Canevari, S. Miotti, S. Ménard et al., Gene Transfection and Expression of the Ovarian Carcinoma Marker Folate Binding Protein on NIH/3T3 Cells Increases Cell Growth in Vitro and in Vivo, Cancer Res, vol.53, issue.23, pp.5791-5797, 1993.

E. Daraï, J. Scoazec, F. Walker-combrouze, N. Mlika-cabanne, G. Feldmann et al., Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases, Human Pathology, vol.28, issue.8, pp.922-930, 1997.
DOI : 10.1016/S0046-8177(97)90007-1

K. Sawada, A. Mitra, A. Radjabi, V. Bhaskar, E. Kistner et al., Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via ??5-Integrin, which Is a Therapeutic Target, Cancer Research, vol.68, issue.7, pp.2329-2368, 2008.
DOI : 10.1158/0008-5472.CAN-07-5167

C. Leamon, J. Reddy, R. Dorton, A. Bloomfield, K. Emsweller et al., Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates, Journal of Pharmacology and Experimental Therapeutics, vol.327, issue.3, pp.918-943, 2008.
DOI : 10.1124/jpet.108.143206

C. Leamon and P. Low, Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis., Proceedings of the National Academy of Sciences, vol.88, issue.13, pp.5572-5578, 1991.
DOI : 10.1073/pnas.88.13.5572

H. Itamochi and J. Kigawa, Clinical trials and future potential of targeted therapy for ovarian cancer, International Journal of Clinical Oncology, vol.90, issue.5, pp.430-470, 2012.
DOI : 10.1007/s10147-012-0459-8

L. Kelemen, The role of folate receptor ?? in cancer development, progression and treatment: Cause, consequence or innocent bystander?, International Journal of Cancer, vol.257, issue.2, pp.243-50, 2006.
DOI : 10.1002/ijc.21712

L. Crane, M. Van-oosten, R. Pleijhuis, A. Motekallemi, S. Dowdy et al., Intraoperative imaging in ovarian cancer: fact or fiction? Mol Imaging, 2011.

M. Werner, S. Karve, R. Sukumar, N. Cummings, J. Copp et al., Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis, Biomaterials, vol.32, issue.33, pp.8548-54, 2011.
DOI : 10.1016/j.biomaterials.2011.07.067

M. Figini, R. Ferri, D. Mezzanzanica, M. Bagnoli, E. Luison et al., Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies, Gene Therapy, vol.10, issue.12, pp.1018-1043, 2003.
DOI : 10.1038/sj.gt.3301962

W. Ebel, E. Routhier, B. Foley, S. Jacob, J. Mcdonough et al., Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha Available from, Cancer Immun J Acad Cancer Immunol [Internet], vol.7, 2007.

. Pegylated-liposomal-doxorubicin, PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer, J ClinOncol, 2013.

M. Razzak, Gynaecological cancer: Vintafolide???targeting the folate receptor with a cytotoxic offers hope, Nature Reviews Clinical Oncology, vol.10, issue.12, p.668, 2013.
DOI : 10.1038/nrclinonc.2013.201